Related Experiment Video

Updated: Mar 8, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.6K

Long Noncoding RNAs in Pathological Cardiac Remodeling

Janika Viereck1, Thomas Thum2

  • 1From the Institute of Molecular and Translational Therapeutic Strategies, IFB-Tx (J.V., T.T.) and Excellence Cluster REBIRTH (T.T.), Hannover Medical School, Germany; and National Heart and Lung Institute, Imperial College London, United Kingdom (T.T.).

Circulation Research
|January 21, 2017
PubMed

Insights

A new long noncoding RNA, Chaer, regulates cardiac hypertrophy epigenetically. This discovery enhances understanding of cardiovascular disease mechanisms.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Epigenetics

Background:

  • Cardiac hypertrophy is a significant risk factor for cardiovascular disease.
  • The precise molecular mechanisms underlying cardiac hypertrophy remain incompletely understood.
  • Long noncoding RNAs (lncRNAs) are emerging as critical regulators in various biological processes.

Purpose of the Study:

  • To identify and characterize novel regulatory elements involved in cardiac hypertrophy.
  • To elucidate the role of lncRNAs in the epigenetic regulation of cardiac hypertrophy.
  • To provide new insights into the pathogenesis of cardiovascular disease.

Main Methods:

  • Identification of novel lncRNAs using transcriptomic analysis.
  • Functional characterization of candidate lncRNAs in cardiac cell models.
  • Investigation of epigenetic modifications associated with lncRNA regulation.

Main Results:

  • A novel lncRNA, designated Chaer, was identified.
  • Chaer was found to act as a noncoding epigenetic regulator.
  • Chaer plays a role in the early stages of cardiac hypertrophy.

Conclusions:

  • Chaer represents a novel epigenetic regulator in cardiac hypertrophy.
  • Understanding Chaer's function offers new perspectives on cardiovascular disease mechanisms.
  • Chaer may serve as a potential therapeutic target for cardiovascular conditions.

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.7K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
699
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
731
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593